Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 0.29 7.41% 0.02
CLDX closed up 7.41 percent on Thursday, January 17, 2019, on 1.52 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical CLDX trend table...

Date Alert Name Type % Chg
Jan 17 Crossed Above 50 DMA Bullish 0.00%
Jan 17 MACD Bullish Centerline Cross Bullish 0.00%
Jan 17 Pocket Pivot Bullish Swing Setup 0.00%
Jan 17 Calm After Storm Range Contraction 0.00%
Jan 17 Upper Bollinger Band Walk Strength 0.00%
Jan 17 Inside Day Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Up 3 Days in a Row Strength 0.00%
Jan 17 Upper Bollinger Band Touch Strength 0.00%
Jan 16 50 DMA Resistance Bearish 7.41%

Older signals for CLDX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Is CLDX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.9
52 Week Low 0.183
Average Volume 1,826,989
200-Day Moving Average 0.5296
50-Day Moving Average 0.2768
20-Day Moving Average 0.2385
10-Day Moving Average 0.263
Average True Range 0.0262
ADX 24.58
+DI 28.1522
-DI 11.087
Chandelier Exit (Long, 3 ATRs ) 0.2414
Chandelier Exit (Short, 3 ATRs ) 0.2616
Upper Bollinger Band 0.2974
Lower Bollinger Band 0.1796
Percent B (%b) 0.94
BandWidth 49.392034
MACD Line 0.0013
MACD Signal Line -0.0074
MACD Histogram 0.0087
Fundamentals Value
Market Cap 37.22 Million
Num Shares 128 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -0.27
Price-to-Sales 32.43
Price-to-Book 1.32
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.34
Resistance 3 (R3) 0.33 0.32 0.33
Resistance 2 (R2) 0.32 0.31 0.32 0.32
Resistance 1 (R1) 0.30 0.30 0.31 0.31 0.32
Pivot Point 0.29 0.29 0.29 0.29 0.29
Support 1 (S1) 0.27 0.28 0.28 0.28 0.26
Support 2 (S2) 0.26 0.27 0.26 0.26
Support 3 (S3) 0.24 0.26 0.25
Support 4 (S4) 0.25